Target-specific delivery of doxorubicin to retinoblastoma using epithelial cell adhesion molecule aptamer

Molecular Vision

Volumn 18, Issue , 2012, Pages 2783-2795

  Subramanian, Nithya ^a,b   Raghunathan, Vaishnavi ^a   Kanwar, Jagat R ^b   Kanwar, Rupinder K ^b   Elchuri, Sailaja V ^a   Khetan, Vikas ^c   Krishnakumar, Subramanian ^a  

^a VISION RESEARCH FOUNDATION   (India)

^b DEAKIN UNIVERSITY   (Australia)

^c MEDICAL RESEARCH FOUNDATION   (India)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; DOXORUBICIN; EPITHELIAL CELL ADHESION MOLECULE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CELL PROLIFERATION; CELL TRANSPORT; CONTROLLED STUDY; DRUG BINDING SITE; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG RELEASE; DRUG SYNTHESIS; DRUG TARGETING; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GLIA CELL; HUMAN; HUMAN CELL; MUELLER CELL; PRIORITY JOURNAL; RETINOBLASTOMA; SPECTROFLUOROMETRY; TUMOR CELL LINE;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, NEOPLASM; APTAMERS, NUCLEOTIDE; BIOLOGICAL TRANSPORT; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; DOXORUBICIN; DRUG CARRIERS; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; MOLECULAR TARGETED THERAPY; NEUROGLIA; ORGAN SPECIFICITY; PROTEIN BINDING; RETINAL NEOPLASMS; RETINOBLASTOMA; SPECTROMETRY, FLUORESCENCE; TUMOR MARKERS, BIOLOGICAL;

EID: 84870448531     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. McLean IW, Burnier MN, Zimmerman LE, Jakobiec FA. Tumors of the retina. In: Tumors of the Eye and Ocular Adnexa. Washington, DC: Armed Forces Institute of Pathology; 1994:97-149.
2. Parulekar MV. Retinoblastoma - Current treatment and future direction. Early Hum Dev 2010; 86:619-25. [PMID: 20889272].
3. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990; 249:505-10. [PMID: 2200121].
4. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature 1990; 346:818-22. [PMID: 1697402].
5. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988; 332:323-7. [PMID: 3127726].
6. Kanwar JR, Roy K, Kanwar RK. Chimeric aptamers in cancer cell-targeted drug delivery. Crit Rev Biochem Mol Biol 2011; 46:459-77. [PMID: 21955150].
7. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995; 1:1311-8. [PMID: 9815926].
8. Song E, Zhu P, Lee SK, Chowdhury D, Kussman S, Dykxhoorn DM, Feng Y, Palliser D, Weiner DB, Shankar P, Marasco WA, Lieberman J. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005; 23:709-17. [PMID: 15908939].
9. Zhou J, Rossi JJ. Aptamer-targeted cell-specific RNA interference. Silence 2010; 1:4-[PMID: 20226078].
10. Vorhies SJ, Nemunaitis JJ. Biologics Targets & Therapy 2007; 1:367-76.
11. Kanwar JR, Mohan RR, Kanwar RK, Roy K, Bawa R. Applications of aptamers in nanodelivery systems in cancer, eye and inflammatory diseases. Nanomedicine (Lond) 2010; 5:1435-45. [PMID: 21128724].
12. Huang YF, Shangguan D, Liu H, Phillips JA, Zhang X, Chen Y, Tan W. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. ChemBioChem 2009; 10:862-8. [PMID: 19253922].
13. Wullner U, Neef I, Eller A, Kleines M, Tur MK, Barth S. Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2. Curr Cancer Drug Targets 2008; 8:554-65. [PMID: 18991566].
14. Chu TC, Marks JW III, Lavery LA, Faulkner S, Rosenblum MG, Ellington AD, Levy M. Aptamer: Toxin conjugates that specifically target prostate tumor cells. Cancer Res 2006; 66:5989-92. [PMID: 16778167].
15. Hicke BJ, Stephens AW, Gould T, Chang YF, Lynott CK, Heil J, Borkowski S, Hilger CS, Cook G, Warren S, Schmidt PG. Tumor targeting by an aptamer. J Nucl Med 2006; 47:668-78. [PMID: 16595502].
16. Hwang do W. Ko HY, Lee JH, Kang H, Ryu SH, Song IC, Lee DS, Kim S. A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer. J Nucl Med 2010; 51:98-105. [PMID: 20008986].
17. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8:755-68. [PMID: 18784658].
18. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med 2006; 355:1253-61. [PMID: 16990388].
19. Sarrio D, Franklin CK, Mackay A, Reis-Filho JS, Isacke CM. Epithelial and Mesenchymal Subpopulations Within Normal Basal Breast Cell Lines Exhibit Distinct Stem Cell/Progenitor Properties. Stem Cells 2012; 30:292-303. [PMID: 22102611].
20. Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, Budhu A, Zanetti KA, Chen Y, Qin L, Tang Z, Wang XW. EpCAM and α-Fetoprotein Expression Defines Novel Prognostic Subtypes of Hepatocellular Carcinoma. Cancer Res 2008; 68:1451-61. [PMID: 18316609].
21. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100:3983-8. [PMID: 12629218].
22. Bapat SA, Mali AM, Koppikar CB, Kurrey NK. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 2005; 65:3025-9. [PMID: 15833827].
23. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414:105-11. [PMID: 11689955].
24. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT, Donahoe PK. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci USA 2006; 103:11154-9. [PMID: 16849428].
25. Terris B, Cavard C, Perret C. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. J Hepatol 2010; 52:280-1. [PMID: 20006402].
26. Munz M, Baeuerie AP, Gires O. The emerging role of EpCAM in stem cell signaling. Cancer Res 2009; 69:5627-[PMID: 19584271].
27. Baeuerle PA, Gires O. EpCAM (CD326) finding its role in cancer Br J Cancer 2007; 96:417-23. [PMID: 17211480].
28. Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M, Kieu C, Papior P, Baeuerle PA, Munz M, Gires O. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 2009; 11:162-71. [PMID: 19136966].
29. Gires O, Klein CA, Baeuerle PA. On the abundance of EpCAM on cancer stem cells. Nat Rev Cancer 2009; 9:143-[PMID: 19132011].
30. Krishnakumar S, Mohan A, Mallikarjuna K, Venkatesan N, Biswas J, Shanmugam MP, Ren-Heidenreich L. EpCAM expression in retinoblastoma: a novel molecular target for therapy. Invest Ophthalmol Vis Sci 2004; 45:4247-50. [PMID: 15557427].
31. Mitra M, Kandalam M, Verma RS. UmaMaheaswari K, Krishnakumar S. Genome-wide changes accompanying the knockdown of EpCAM in retinoblastoma. Mol Vis 2010; 16:828-42. [PMID: 20461151].
32. Mitra M, Kandalam M, Harilal A, Verma RS. Uma Maheshwari K, Swaminathan S, Krishnakumar S. EpCAM is a putative stem cell marker in retinoblastoma effective target for T-cell-mediated immunotherapy. Mol Vis 2012; 18:290-308. [PMID: 22328825].
33. Mitra M, Misra R, Harilal A, Sahoo KS, Krishnakumar S. Enhanced in vitro antiproliferative effects of EpCAM antibody functionalized paclitaxel-loaded PLGA nanoparticles in retinoblastoma cells. Mol Vis 2011; 17:2724-37. [PMID: 22065926].
34. Gires O, Bauerle PA. EpCAM as a target in cancer therapy. J Clin Oncol 2010; 28:e239-40. [PMID: 20385979].
35. Shigdar S, Lin J, Yu Y, Pastuovic M, Wei M, Duan W. RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Sci 2011; 102:991-8. [PMID: 21281402].
36. Tan C, Tasaka H, Yu KP, Murphy ML, Karnofsky DA. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer 1967; 20:333-53. [PMID: 4290058].
37. Lee S, Baek M, Kim H, Ha J, Jeoung D. Mechanism of doxorubicin-induced cell death and expression profile analysis. Biotechnol Lett 2002; 24:1147-51.
38. Bagalkot V, Farokhzad OC, Langer R, Jon S. Aptamer-Doxorubicin Physical Conjugate as a Novel Targeted Drug-Delivery Platform. Angew Chem 2006; 45:1-5.
39. Lee NG, Berry JL, Lee TC, Wang AT, Honowitz S, Murphree AL, Varshney N, Hinton DR, Fawzi AA. Sonoporation enhances chemotherapeutic efficacy in retinoblastoma cells in vitro. Invest Ophthalmol Vis Sci 2011; 52:3868-73. [PMID: 21273549].
40. Ray P, White RR. Aptamers for Targeted Drug Delivery. Pharmaceuticals (Ott) 2010; 3:1761-78.
41. Terris B, Cavard C, Perret C. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. J Hepatol 2010; 52:280-1. [PMID: 20006402].
42. Min K, Jo H, Song K, Cho M, Chun Y, Jon S, Kim JW, Ban C. Dual-aptamer-based delivery vehicle of Doxorubicin to both PSMA (+) and PSMA (-) prostate cancers. Biomaterials 2011; 32:2124-32. [PMID: 21147500].